Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Novel HPV Vaccine in Healthy Women
NCT00231413Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2005
- Primary completion
- Mar 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, randomised trial of HPV-16/18/31/45 L1 AS04 in human papillomavirus infection (7 arms), sponsored by GSK. Primary endpoints: Number of Seroconverted Subjects for Anti-Human Papillomavirus (Anti-HPV)-16 at Month 7, Number of Seroconverted Subjects for Anti-Human Papillomavirus (Anti-HPV)-18 at Month 7 and 2 more. Started Mar 2005; status: completed.
02
Drugs
HPV-16/18/31/45 L1 AS04
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT00231413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00231413.